The short answer
Fasting and cancer is an active area of research, but the evidence is not strong enough to recommend fasting as a cancer treatment or prevention strategy. Laboratory and animal studies provide intriguing biological explanations, and small human studies suggest that carefully selected fasting or fasting-mimicking protocols can be feasible during some cancer treatments. What remains unproven is whether fasting improves cancer control, survival or treatment outcomes.
Research on fasting and cancer is promising enough to justify clinical trials, but not strong enough to replace or modify standard oncology care. Recent reviews find that human studies remain relatively small, heterogeneous and concentrated in certain cancers—especially breast cancer. Some report metabolic changes or possible reductions in treatment-related symptoms, while other systematic reviews have not found convincing reductions in chemotherapy toxicity or improvements in treatment effectiveness.
Key takeaways
- Fasting is not a cancer cure. It should never replace surgery, radiation, chemotherapy, immunotherapy, targeted therapy or other evidence-based treatment.
- Most anticancer findings are still preclinical. Cell and animal studies can identify mechanisms but cannot establish that fasting treats cancer in people.
- Human evidence is early and mixed. Small studies suggest feasibility and measurable metabolic effects, but definitive benefits for tumor control, survival or treatment toxicity have not been established.
- Nutrition can be a major safety issue. Unintentional weight loss, malnutrition, sarcopenia and cancer cachexia can make fasting inappropriate or dangerous.
- Oncology guidance comes first. People receiving cancer treatment should not begin prolonged fasting or a fasting-mimicking diet without discussing it with their cancer-care team.
A 2026 scoping review identified 20 interventional studies involving 871 cancer patients or survivors. Results were heterogeneous and generally came from small or moderate-strength studies. A 2025 systematic review of patients receiving chemotherapy or targeted therapy concluded that evidence was still insufficient to determine whether intermittent fasting improves treatment effectiveness or treatment-related side effects.
The safety question is just as important as the potential benefit. Cancer and its treatments can cause appetite loss, malnutrition, muscle loss and cachexia. For someone already losing weight or struggling to meet nutritional needs, deliberately restricting food may be harmful. Any fasting protocol during active cancer treatment should therefore be discussed with the oncology team and, when appropriate, an oncology dietitian.
Why are scientists studying fasting and cancer?
The scientific interest in fasting and cancer comes from the way nutrient availability affects metabolism and cellular signaling. During fasting, circulating glucose, insulin and insulin-like growth factor signaling can change, while fatty-acid use and ketone production may rise. Researchers have asked whether these changes could create different stress conditions for healthy cells and cancer cells.
Many cancer cells have altered metabolism and growth signaling. In preclinical models, fasting or fasting-mimicking diets have sometimes increased tumor-cell stress or enhanced the effects of anticancer treatments. Researchers have also explored immune signaling, oxidative stress and pathways related to cellular growth and nutrient sensing.
Those mechanisms are biologically interesting, but mechanism is not the same as clinical benefit. A treatment can look compelling in cultured cells or mice and still fail to improve outcomes in people. Human trials are therefore the evidence that matters most for deciding whether a fasting strategy belongs in cancer care.
What do laboratory and animal studies show?
Preclinical research provides much of the enthusiasm surrounding fasting and cancer. Animal studies of fasting and fasting-mimicking diets have reported slower tumor progression in some models and possible enhancement of chemotherapy, hormone therapy, targeted therapy or immunotherapy. Proposed explanations include changes in glucose and growth-factor signaling, oxidative stress, autophagy-related pathways and immune responses.
A 2026 systematic review of fasting-mimicking diets found encouraging antitumor effects across preclinical animal studies. That finding helps justify human trials, but the review itself evaluated animal models rather than proving benefit in patients. The distinction is essential: preclinical evidence can generate a hypothesis; it cannot tell a patient that fasting will shrink a tumor or improve survival.
What do human studies show so far?
The human evidence on fasting and cancer is substantially less certain. Clinical studies have tested short-term fasting, time-restricted eating and fasting-mimicking diets in different populations and around different treatments. Protocols vary widely in duration, calorie intake, cancer type, stage and treatment.
A 2026 scoping review mapped 20 interventional studies with 871 participants. Some studies reported less fatigue, changes in insulin or IGF-1, or lower treatment toxicity, but results were inconsistent and weight loss occurred in many studies. The authors characterized the overall evidence as limited and fragmented rather than definitive.
A separate 2025 systematic review focusing on chemotherapy and targeted therapy found fasting to be feasible in the included studies but concluded that robust evidence was lacking for improved treatment outcomes or reduced treatment toxicity. Earlier meta-analysis likewise found no significant overall reduction in chemotherapy adverse events compared with non-fasting approaches.
In other words, the current human literature supports continued research—not a claim that fasting has been established as an anticancer therapy.
What is a fasting-mimicking diet?
A fasting-mimicking diet, often abbreviated FMD, is a short, calorie-restricted eating protocol designed to reproduce some metabolic features of fasting while still providing limited food. Research protocols often reduce calories, protein and carbohydrate for several days and then return participants to their usual diet.
FMD research is relevant to fasting and cancer because some early-phase trials have found these protocols feasible in carefully selected patients at low nutritional risk. Studies have documented changes in glucose, insulin-related signaling, growth factors and immune markers. These biological changes are not the same as proof of improved survival or tumor response, however, and larger randomized trials are needed.
Can fasting make chemotherapy work better?
That possibility is being investigated, but it is not established. Preclinical models have produced hypotheses about making cancer cells more vulnerable to treatment while helping normal cells tolerate stress. Early clinical trials have examined whether fasting around chemotherapy changes toxicity, blood counts, quality of life or metabolic markers.
Results remain inconsistent. A systematic review and meta-analysis found no evidence that therapeutic fasting was superior to non-fasting diets for preventing chemotherapy toxicity. A newer 2025 review similarly concluded that evidence was insufficient to determine an effect on treatment effectiveness or side effects. Patients should therefore not time fasting around chemotherapy on their own.
Does fasting prevent cancer?
There is currently no good human evidence that fasting itself prevents cancer. This is an important limit in discussions of fasting and cancer. Body weight, physical activity, tobacco exposure, alcohol, infections, genetics, environmental exposures and dietary patterns can all influence cancer risk, and different cancers have different causes.
Intermittent fasting may help some people manage weight or metabolic risk factors, but it would be an overreach to convert those effects into a claim that fasting prevents cancer. Cancer prevention recommendations should remain grounded in established evidence such as avoiding tobacco, maintaining an appropriate weight, being physically active, limiting alcohol, receiving recommended vaccines and screening, and following an overall nutritious dietary pattern.
What about autophagy and cancer?
Autophagy is a normal cellular recycling and stress-response process, and fasting can influence nutrient-sensing pathways related to autophagy. Online discussions sometimes simplify this into the claim that fasting “activates autophagy” and therefore destroys cancer cells. Cancer biology is much more complicated.
Autophagy can have different roles at different stages of cancer. In some settings it may help suppress early cellular damage; in established tumors, cancer cells may also use autophagy to survive metabolic stress. There is no validated fasting-hour threshold at which human anticancer autophagy suddenly begins, and autophagy is not a reason to substitute fasting for oncology treatment.
Could fasting be harmful during cancer treatment?
Yes. The largest practical concern in fasting and cancer is nutritional risk. Cancer and treatment can reduce appetite, change taste, cause nausea or swallowing problems, interfere with nutrient absorption and increase metabolic demands. The National Cancer Institute notes that malnutrition can progress to cancer cachexia, a wasting syndrome involving loss of muscle and fat.
Loss of skeletal muscle can affect strength, function and the ability to tolerate treatment. Someone who is underweight, losing weight unintentionally, malnourished or developing cachexia should not assume that additional dietary restriction is beneficial. Nutrition support may be a treatment priority.
Other concerns include dehydration, dizziness, low blood pressure, low blood glucose, medication interactions and difficulty recovering between treatments. Risk varies substantially by cancer type, treatment, nutritional status and other medical conditions.
Who should be especially cautious?
Fasting during active cancer care deserves particular caution for people with unintentional weight loss, low body weight, malnutrition, sarcopenia or cachexia; people who have difficulty eating or absorbing nutrients; and those whose treatment already causes substantial nausea, vomiting or diarrhea.
Diabetes and glucose-lowering medications add another layer of risk. Pregnancy, breastfeeding, eating-disorder history, significant kidney or liver disease and frailty can also make fasting inappropriate. This is why clinical studies usually use eligibility criteria and monitoring rather than simply telling all patients to fast.
How should patients discuss fasting with an oncology team?
If someone with cancer is interested in fasting, a useful conversation begins with the goal. Is the person hoping to reduce treatment side effects, improve metabolic health, manage weight or participate in a clinical trial? The oncology team can then consider nutritional status, medications, treatment schedule and whether evidence exists for that particular situation.
Ask whether an oncology dietitian should be involved and whether weight, muscle mass, hydration, glucose or laboratory values require monitoring. For experimental fasting protocols, participation in a properly designed clinical trial is generally more informative and safer than attempting to reproduce a research diet independently.
Fasting and cancer: what we know versus what we do not know
| Question | What the evidence supports |
|---|---|
| Does fasting change metabolism? | Yes. Fasting can alter glucose, insulin, fatty-acid use, ketones and growth-factor signaling. |
| Are there anticancer effects in laboratory models? | Yes, in some cell and animal models. These results do not establish human treatment benefit. |
| Is fasting feasible for some cancer patients? | Small clinical studies suggest that selected, monitored patients can complete certain fasting or FMD protocols. |
| Does fasting reduce chemotherapy side effects? | Evidence is mixed; systematic reviews have not established a consistent benefit. |
| Does fasting improve survival or cure cancer? | No convincing clinical evidence establishes this. |
| Can fasting be risky? | Yes, particularly with weight loss, malnutrition, muscle loss, cachexia, diabetes or treatment-related eating problems. |
Frequently asked questions
Can fasting starve cancer cells?
The phrase is misleading. Cancer cells depend on nutrients, but so do healthy tissues and the immune system. The body also maintains circulating fuels during fasting. Researchers are studying whether temporary nutrient changes can alter treatment sensitivity, but patients cannot selectively starve a tumor simply by not eating.
Is intermittent fasting safe after cancer treatment?
It depends on recovery, nutritional status, medications and the person’s goals. Survivorship is different from active treatment, but anyone with persistent weight loss, nutritional deficiencies or other medical concerns should obtain individualized guidance.
Should someone fast before chemotherapy?
Not unless the oncology team approves it. The evidence has not established a universal fasting protocol around chemotherapy, and individual nutritional and medication risks matter.
Is a fasting-mimicking diet cancer treatment?
No. FMDs are experimental adjunctive strategies being studied alongside standard treatments. They are not replacements for evidence-based cancer therapy.
What is the most important takeaway about fasting and cancer?
The research is scientifically interesting but clinically incomplete. The safest interpretation is to view fasting as an investigational nutritional strategy in oncology—not as a proven method to prevent, treat or cure cancer.
Where to go next
Sources & further reading
- Fasting-Based Dietary Interventions in Cancer Patients and Survivors: A Scoping Review (2026)
- Impact of intermittent fasting on patients with cancer undergoing chemotherapy and/or targeted therapies: systematic review (2025)
- Therapeutic Fasting in Reducing Chemotherapy Side Effects: systematic review and meta-analysis
- Fasting-mimicking diets and tumor metabolism: systematic review of preclinical evidence (2026)
- National Cancer Institute: Nutrition During Cancer Treatment
- National Cancer Institute: Cancer Cachexia
Editorial standard: Fasting Metabolic Health prioritizes human clinical evidence, distinguishes preclinical findings from patient outcomes, and does not present fasting as a substitute for established cancer prevention or treatment.